Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference

From Startup Arbutus Bio

Link to Full Article: http://investor.arbutusbio.com/news-releases/news-release-details/arbutus-participate-2018-b-riley-fbr-healthcare-conference

WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, will participate in the Hepatitis B Functional Cure Panel at the B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 9:50 am – 10:50 am ET in New York.
About ArbutusArbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Mark MurrayPresident and CEOPhone: 604-419-3200 Email: ir@arbutusbio.com
Pam MurphyInvestor Relations ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com

Source: Arbutus Biopharma Corporation

Please visit their site for more information: Arbutus Bio.com

All,Biotechnology,Healthcare News,Startup News
2018-08-29 06:10:02